DDAVP® Rhinal Tube (desmopressin acetate) Rx only DESCRIPTION DDAVP® Rhinal Tube (desmopressin acetate) is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. The risk of developing TD increases with duration of treatment and total cumulative dosage. However, methylene blue may cause hemolytic anemia in patients with G6PD deficiency, which may be fatal.Hemodialysis and continuous ambulatory peritoneal dialysis do not remove significant amounts of metoclopramide.Metoclopramide hydrochloride, the active ingredient in Gimoti, is a dopamine-2 receptor antagonist. GIMOTI is a prescription medicine used for 2 to 8 weeks to relieve symptoms in adults with diabetes who have irregular or slow stomach emptying. • Noctiva has not been studied in patients less than 50 years of age. • Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. DDAVP (desmopressin acetate) is an antidiuretic and antihemorrhagic drug used to treat bed-wetting, central DDAVP can infrequently cause low levels of sodium in the blood, which can be serious and possibly life-threatening. DDAVP Injection 4 mcg/mL contains as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. This information should not take the place of you talking with your doctor or healthcare professional. In some patients, symptoms may lessen or resolve after metoclopramide is stopped Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use Strong CYP2D6 Inhibitors, not Included in Antipsychotic Category AboveDopaminergic Agonists and Other Drugs that Increase Dopamine ConcentrationsDopaminergic Agonists and Drugs Increasing Dopamine ConcentrationsDrugs with Absorption Altered due to Increased Gastrointestinal MotilityDrugs with Decreased Absorption (e.g., digoxin, atovaquone, posaconazole oral suspensionDrugs with Increased Absorption (e.g., sirolimus, tacrolimus, cyclosporine)Before taking Gimoti, tell your healthcare provider about all of your medical conditions, including if you:Especially tell your healthcare provider if you take:Know the medicines you take. Copyright 2017 Evoke Pharma | All Rights Reserved | Site Developed By GIMOTI is a prescription medicine used for 2 to 8 weeks to relieve symptoms in adults with diabetes who have irregular or slow stomach emptying. Nasal delivery is possible because the thickness of mucosa of the nasal cavity is a single epithelial cell layer which is well vascularized and allows metoclopramide molecules to be transferred directly to the systemic circulation without ingesting oral tablets. An increase in mammary neoplasms was found in rodents after chronic administration of metoclopramide Metoclopramide at intramuscular doses up to 20 mg/kg/day (about 3 times the maximum recommended human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.The effectiveness of Gimoti has been established based on studies of oral metoclopramide for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.Gimoti (metoclopramide) nasal spray is supplied as a solution of metoclopramide in a 10 mL Type 1 amber glass bottle fitted with a metered spray pump attachment, a protective cap, and a safety clip. Seek immediate medical attention if you have symptoms of low levels of sodium in the blood, including:
See full prescribing information for DDAVP NASAL SPRAY. Also tell your healthcare provider if you are pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed, or drink alcohol. DDAVP may interact with carbamazepine, chlorpromazine, lamotrigine, oxybutynin,
The safety and effectiveness of Gimoti in pediatric patients have not been established.Dystonias and other extrapyramidal symptoms associated with metoclopramide are more common in pediatric patients than in adults Metoclopramide is known to be substantially excreted by the kidney, and the risk of adverse reactions, including tardive dyskinesia (TD), may be greater in patients with impaired renal function The clearance of metoclopramide is decreased and the systemic exposure is increased in patients with moderate to severe renal impairment compared to patients with normal renal function, which may increase the risk of adverse reactions Patients with severe hepatic impairment (Child-Pugh C) have reduced systemic metoclopramide clearance (by approximately 50%) compared to patients with normal hepatic function Metoclopramide, by producing a transient increase in plasma aldosterone, may increase the risk of fluid retention in patients with hepatic impairment Metoclopramide-treated patients with NADH-cytochrome bMetoclopramide is a substrate of CYP2D6.